Form 4: AVNS Director Gary Blackford Acquires 60,000 Shares
Rhea-AI Filing Summary
Gary Blackford, a director of Avanos Medical, Inc. (AVNS), reported purchases of a total of 60,000 shares on 08/13/2025 in two grouped transactions: 20,000 shares acquired at a weighted-average price of $10.975 and 40,000 shares acquired at a weighted-average price of $10.995.
Following these transactions the filing shows 91,593 shares beneficially owned directly and 40,000 shares held indirectly in trusts for immediate family members (the reporting person is co-trustee and disclaims beneficial ownership except to the extent of pecuniary interest). The Form 4 was signed by an attorney-in-fact on 08/15/2025.
Positive
- None.
Negative
- None.
Insights
TL;DR: Director acquired 60,000 shares in two purchases at roughly $10.98, increasing both direct and indirect holdings.
The Form 4 documents two purchase transactions on 08/13/2025 totaling 60,000 common shares at weighted-average prices of $10.975 and $10.995. After the transactions, the reporting line shows 91,593 shares held directly and 40,000 held indirectly in family trusts. The filing includes standard footnotes disclosing price ranges for the multiple trades and a disclaimer of beneficial ownership for the trust-held shares. This disclosure is routine insider reporting required by Section 16 and provides clear, transaction-level transparency.
TL;DR: Director purchases documented; trust holdings disclosed with co-trustee status and disclaimer of beneficial ownership.
The Form 4 properly reports purchases aggregated as weighted-average prices and supplies explanatory footnotes about trade price ranges and trust arrangements. The reporting person is identified as a director and co-trustee for shares held in trusts for immediate family members, with a disclaimer limiting beneficial ownership to pecuniary interest. The form appears complete for the transactions reported and is signed by an attorney-in-fact on behalf of the reporting person.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Purchase | Common Stock | 20,000 | $10.975 | $220K |
| Purchase | Common Stock | 40,000 | $10.995 | $440K |
Footnotes (1)
- The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $10.94 to $11.01, inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $10.98 to $11.04, inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. These shares are held in trusts for the benefit of certain immediate family members of the Reporting Person. The Reporting Person is co-trustee of such trusts. The Reporting Person disclaims beneficial ownership of these shares except to the extent of his pecuniary interest, and the filing of this report is not an admission that the Reporting Person is the beneficial owner of these shares for purposes of Section 16 or for any other purpose.
